Philip Morris International (PM) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
24 Jul, 2026Executive summary
Q2 and H1 2026 delivered strong double-digit growth in net revenues, gross profit, and adjusted diluted EPS, driven by robust international smoke-free product (SFP) and combustible performance, with IQOS and ZYN leading growth and expansion into 109 markets.
U.S. segment showed sequential improvement in net revenue and gross profit, supported by ZYN portfolio expansion and new product launches, though full H1 U.S. net revenues declined due to inventory movements and higher manufacturing costs.
Net earnings attributable to shareholders declined 8.3% to $5.3B, and reported diluted EPS fell 8.4% to $3.36, primarily due to a $511M non-cash impairment on the RBH equity investment and higher effective tax rate.
On track for another year of best-in-class top and bottom-line growth, with continued investment in SFPs and premium brands.
Financial highlights
Q2 2026 net revenues reached $11.2B (+10.4% YoY), gross profit $7.7B (+11.5%), and adjusted diluted EPS $2.20 (+15.2%), while reported diluted EPS was $1.80 (-7.7%) due to impairment.
H1 2026 net revenues totaled $21.3B (+9.8%), gross profit $14.6B (+10.9%), operating income $8.4B (+16.1%), and adjusted diluted EPS $4.16 (+15.6%).
Net cash from operating activities was $5.1B in H1, with full-year projection at ~$13.5B; capital expenditures expected at $1.4–$1.6B, mainly for smoke-free manufacturing.
International SFP net revenues grew 13.7–19.2% in H1, with shipment volume up 7.5–9.9%; international combustibles net revenues up 3.8–8.4%.
U.S. ZYN shipment volumes up 1.8–2% in Q2, but U.S. net revenues down 16.1% YoY in H1.
Outlook and guidance
Full-year 2026 guidance: organic net revenue growth of 5–7%, organic operating income growth of 7–9%, and adjusted diluted EPS of $8.26–$8.41 (+9.5–11.5%), with a $0.15 currency tailwind.
Shipment volume expected to be stable to slightly positive, with high single-digit SFP growth offsetting a 2–3% decline in cigarette volumes.
Q3 2026 guidance: mid-single-digit organic top-line growth, modest margin expansion, and adjusted diluted EPS of $2.20–$2.25.
Operating cash flow projected at ~$13.5B; net debt to adjusted EBITDA targeted near 2.0x by year-end.
Latest events from Philip Morris International
- Smoke-free products drive robust growth, profitability, and superior shareholder returns.PM
Conference presentation31 Jul 2026 - 2025 EPS guidance targets 13–15% growth, led by robust smoke-free product expansion and margin gains.PM
Barclays 18th Annual Global Consumer Staples Conference 202516 Jul 2026 - Smoke-free products and innovation drive growth, with ZYN and IQOS leading global expansion.PM
Morgan Stanley Global Consumer & Retail Conference 20259 Jul 2026 - Raised 2024 guidance after record H1 growth, led by IQOS and ZYN, with margin expansion.PM
Q2 20248 Jul 2026 - Smoke-free product momentum and multi-category strategy drive robust 2025 financial outlook.PM
2025 dbAccess Global Consumer Conference29 Jun 2026 - Smoke-free product momentum and raised EPS guidance highlight strong 2024 growth outlook.PM
21st Annual dbAccess Global Consumer Conference29 Jun 2026 - Smoke-free products drive growth, with ZYN ULTRA and IQOS expanding amid regulatory progress.PM
23rd annual dbAccess Global Consumer Conference2 Jun 2026 - Strong financial and smoke-free growth, dividend increase, and all board proposals but one approved.PM
AGM 20268 May 2026 - Adjusted EPS up 16% to $1.96, with smoke-free products now 43% of revenue, led by IQOS.PM
Q1 202624 Apr 2026